Survival rate after formulation (%) | |||||||
---|---|---|---|---|---|---|---|
Factor | Treatment | 7 d | 14 d | 21 d | 28 d | 35 d | MSt (days ± SE) |
EPN |
|
15 | 0 | 0 | 0 | 0 | 8.05 ± 0.079 |
|
79 | 79 | 58.8 | 58.8 | 0 | 26.07 ± 0.389 | |
|
93.5 | 93.5 | 51.4 | 0 | 0 | 22.00 ± 0.209 | |
Prec |
|
39.6 | 39.6 | 22.5 | 0 | 0 | 13.21 ± 0.262 |
|
53.3 | 23 | 9.8 | 0 | 0 | 13.02 ± 0.218 | |
|
69.3 | 69.3 | 7.6 | 0 | 0 | 14.69 ± 0.182 | |
C |
|
20 | 0 | 0 | 0 | 0 | 8.40 ± 0.088 |
|
79 | 79 | 41.6 | 41.6 | 0 | 26.96 ± 0.355 | |
|
100 | 100 | 30.5 | 21.7 | 0 | 22.22 ± 0.262 | |
Prec-C |
|
40 | 0 | 0 | 0 | 0 | 9.80 ± 0.108 |
|
74.4 | 67.8 | 31.5 | 31.5 | 10 | 22.06 ± 0.372 | |
|
92.4 | 0 | 0 | 0 | 0 | 13.46 ± 0.058 |
Infectivity after formulation (%)a | |||||||||
---|---|---|---|---|---|---|---|---|---|
Factor | Treatment | 7 d | 14 d | 21 d | 28 d | 35 d | Mean IN (% ± SE) |
|
|
EPN |
|
15b | 0b | 0b | 0b | 0b | 3 ± 2.19bc | 6.28 | 0.023 |
|
100a | 100a | 100a | 100a | 0a | 80 ± 9.18a | |||
|
90a | 100a | 0b | 0b | 0a | 38 ± 10.8ac | |||
Prec |
|
75a | 70a | 0a | 0a | 0a | 29 ± 9.5bc | 5.79 | 0.006 |
|
100a | 100a | 55a | 0a | 0a | 51 ± 11.3a | |||
|
100a | 90a | 0a | 0a | 0a | 38 ± 10.8ac | |||
C |
|
35b | 0b | 0b | 0b | 0a | 7 ± 3.3b | 219.59 | <0.001 |
|
100a | 100a | 100a | 80a | 0a | 76 ± 9.58a | |||
|
100a | 100a | 90a | 95a | 0a | 77 ± 9a | |||
Prec-C |
|
40b | 10b | 0b | 00b | 0b | 10 ± 5.7b | 160.54 | <0.001 |
|
100a | 100a | 90a | 90a | 100a | 96 ± 2.7a | |||
|
90a | 10b | 0b | 0b | 0b | 20 ± 8.46b |